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BACKGROUND: Hepatitis B virus (HBV) persists at low replicative levels among 
chronic hepatitis B (CHB) patients after hepatitis B surface antigen (HBsAg) 
seroclearance. The performance of novel HBV serologic assays among this group of 
patients is undetermined. METHODS: We used a highly-sensitive HBsAg (hs-HBsAg) 
assay employing a semi-automated immune complex transfer chemiluminescence 
enzyme technique (ICT-CLEIA, Sysmex, Kobe, Japan) for the detection of HBsAg. The 
lower limit of detection is 0.0005 IU/mL, 100 times more sensitive than conventional 
HBsAg assays. We recruited CHB patients achieving HBsAg seroclearance with hs-
HBsAg measured at the time of HBsAg seroclearance and 6–12 months after HBsAg 
seroclearance as documented by Elecsys HBsAg II (Roche Diagnostics, Branchburg, NJ). 
RESULTS: 75 patients (mean age 49.7 years, 76 % male, genotype B/C distribution 
57.3/42.7 % respectively) were recruited, of which 25 (33.3 %) were on nucleoside 
analogue therapy (median duration of therapy 6.0 years). Six patient had detectable HBV 
DNA ([20 IU/mL) at HBsAg seroclearance; there was no detectable HBV DNA in all 
patients 6–12 months after HBsAg seroclearance. 59 (78.7 %) and 45 (60.0 %) patients 
were hs-HBsAg positive at time of HBsAg seroclearance and 6–12 months after HBsAg 
seroclearance respectively (median detectable levels 0.042 and 0.013 IU/mL 
respectively). For all 150 measurements, a positive antibody to HBsAg (anti-HBs,[10 m 
IU/mL) was borderline associated with a negative hs-HBsAg (p = 0.052). Patients with 
positive anti-HBs, compared to patients with negative anti-HBs, had significantly lower 
median hs-HBsAg levels (0.002 and 0.010 IU/mL respectively, p = 0.019). 
CONCLUSION: Serum hs-HBsAg achieved high rates of detectability among CHB 
patients with HBsAg seroclearance. Anti-HBs positivity was associated with lower hs-
HBsAg levels. Serum hs-HBsAg could potentially assist the differentiation of occult 
hepatitis B patients from individuals with only past HBV exposure. 
